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T he 2009 infl uenza A(H1N1) (A[H1N1]
) is a singlestranded RNA virus that commonly infects the lungs, causing signifi cant morbidity and mortality worldwide. Although the molecular pathogenesis of the infl uenza virus is not completely understood, infl uenza A activates primary human cells, including fl respiratory epithelial cells, neutrophils, and alveolar macrophages. 1,2 This cellular activation may lead to increased systemic infl ammation and the development of acute lung injury (ALI)/ARDS in A(H1N1). 3 To date, the roles of platelets in A(H1N1) remain largely uninvestigated. Although thrombocytopenia and thrombosis occur in infected patients, 4, 5 in vivo platelet activation as a mechanism for these complications is unexplored. Mouse models 6, 7 and clinical observations 3, 8 indicate that systemic inflammation fl and a prothrombotic state are triggered by influenza fl infection. There is evidence that human and rodent platelets have a receptor for infl uenza viruses and that infl uenza can associate with the platelet surface and be internalized. 9 Platelets are now known to be effectors of dysregulated infl ammatory responses in fl addition to pathologic hemostasis in systemic infections. [10] [11] [12] For example, platelets interact with and signal circulating monocytes. 10, 13 In addition, however, they have multiple other infl ammatory activifl ties in infections and in noninfectious inflammatory fl syndromes. 14 Thus, platelets are positioned to play central roles in systemic responses to A(H1N1) infections. Given that influenza may interact with platelets fl and leukocytes, we hypothesized that patients with A(H1N1) and respiratory failure would demonstrate average ( Ϯ SEM) time between phlebotomy and preparation for flow cytometry was 32 ( fl Ϯ 2) min and did not differ between groups. The fi rst 3 mL of blood was discarded, and samples with gross hemolysis or clotting were not used. Platelet activation was measured both in unstimulated and thrombin-receptor activating peptide (TRAP)-stimulated conditions (5 mM for 15 min). All antibodies and reagents were obtained from BD Biosciences unless otherwise specified. fi
To measure PAC-1 (antibody that binds to the active conformation of integrin a IIb b 3 ) binding, whole blood (20 mL) was diluted in Hepes-Tyrodes buffer (180 m L) and then costained (10 m L) with CD41 phycoerythrin, a selective marker of platelets, and the anti-human mouse monoclonal antibody PAC-1 fluores-fl cein isothiocyanate (FITC), which recognizes the active conformation of integrin a IIb b 3 . Samples were then incubated at 25°C in the dark for 10 min and fi xed in fl uorescence-activated cell fl sorter buffer (250 uL). Platelets were selected by gating a total of 10,000 CD41 1 events on a two-parameter dot plot displaying both side scatter (SSC) and forward scatter. The percentage of platelets binding to PAC-1 was adjusted for any nonspecific binding. fi For detection of platelet-monocyte aggregate (PMA) formation, whole blood (800 m L) was diluted in Hepes-Tyrodes buffer (2.4 mL). Fluorescence-activated cell sorter buffer (250 mL) was subsequently added to the blood for 10 min at 25°C in the presence of CD41 phycoerythrin and CD14-FITC, a monocyte marker. Monocytes were selected by gating a total of 1,500 CD41 1 events on a two-parameter dot plot displaying SSC vs CD14-FITC. Single platelets were excluded using a combination of forwardscatter and SSC and positive anti-CD14 fl uorescence. The percentage of platelet-marker-positive monocyte conjugates was measured to represent the percentage of monocytes with one or more adherent platelets. The total numbers of PMA were adjusted for any nonspecifi c binding and displayed as the fraction fi of monocytes with one or more adherent platelets.
Cytokine and Statistical Analyses
Commercially available sandwich enzyme-linked immunosorbent assays were used to determine IL-6 (manufacturer's limit of detection, 0.7 pg/mL) and tumor necrosis factor a (TNF-a ) (manufacturer's limit of detection 5.5 pg/mL) levels from plateletpoor plasma (R&D). Statistical analyses were performed with STATA (version 11.0, StataCorp). Parametric t tests were used for continuous variables and the x 2 test for categorical variables between groups. A one-way analysis of variance was used to compare categorical variables among three-group indices. Logistic linear regression analysis was used to identify correlations between cytokine levels, platelet activation indices, and illness severity. Post hoc analyses were performed using Tukey honestly signifi-fi cant difference pairwise comparisons for unequal groups. Statistical signifi cance was predetermined at P , .05.
Results
Hypotension requiring vasopressor support (eg, shock) was common in patients with A(H1N1) and bacterial pneumonia (35% vs 20%, P 5 .33) ( Table 1 ) . There were no signifi cant differences in either age or sex between groups ( Table 1 ) . As expected given the inclusion criteria of ALI/ARDS, most patients required mechanical ventilation (80% of patients with A[H1N1] and 100% of patients with bacterial pneumonia, P 5 .07). Volume control was the most common mode of mechanical ventilation in the intubated, marked in vivo platelet activation exceeding responses seen in matched patients with bacterial pneumonia.
Materials and Methods
Patient Enrollment
The University of Utah and Intermountain Health Care institutional review boards approved this study (protocols 28210 and 1005443), and all subjects provided written, informed consent. This was a prospective study of two groups of ICU patients aged Ն 21 years with ALI/ARDS enrolled within 24 h of hospital admission. The fi rst group were patients with primary A(H1N1) (n 5 20). The second group were patients with bacterial pneumonia (n 5 15). For comparison, a third group of nonhospitalized, healthy, control subjects (n 5 10) were also prospectively studied. Two investigators (M. T. R. and B. B.) matched the groups on age, sex, and admission APACHE (Acute Physiology and Chronic Health Evaluation) II scores. 15 To minimize bias during the matching process, investigators were blinded to prespecified confi founding variables, including comorbidities, hemodynamic and respiratory parameters, vasopressor support, clinical laboratory data, mortality, and length of ICU stay.
Primary A(H1N1) was diagnosed by reverse transcription polymerase chain reaction performed on an appropriate respiratory sample obtained via nasopharyngeal or throat swab (RealTime Ready Infl uenza A/H1N1 Detection Set; Roche Applied Science). Patients were treated with the antiviral agent oseltamivir (75 mg bid). Patients with A(H1N1) and concurrent secondary bacterial infections were excluded. Pneumonia was diagnosed in patients with typical signs and symptoms of pneumonia and a demonstrable infiltrate by consensus criteria. fi 16, 17 All patients with pneumo nia were treated with antibiotic therapies chosen at the discretion of the primary ICU team. Clinical laboratory variables were determined from blood samples drawn in parallel with blood samples used for platelet activation and cytokine analyses. Patients were followed prospectively for all-cause, in-hospital mortality.
Flow Cytometry
Whole blood, drawn from healthy subjects or from infected patients within 24 h of ICU admission, was collected into sterile acid-citrate-dextrose Vacutainer tubes. Blood was stored in acidcitrate-dextrose until fl ow cytometry testing was performed. The onstrated higher baseline levels of PAC-1 binding compared with patients with bacterial pneumonia and healthy control subjects ( Fig 1B ) . In patients with A(H1N1) with shock (n 5 7) compared with patients with A(H1N1) without shock (n 5 13), PAC-1 binding (15.8% Ϯ 10.2% vs 6.1% Ϯ 4.7%, P 5 .17) and levels of PMA (25.1% Ϯ 11.1% vs 19.4% Ϯ 4.5%, P 5 .29) trended higher, although the differences did not reach statistical significance. fi Upon ex vivo stimulation with TRAP, PAC-1 binding was signifi cantly lower in patients with A(H1N1) or bacterial pneumonia compared with healthy control subjects ( Fig 1D ) . In contrast, levels of PMA with TRAP stimulation did not differ between the three groups ( Fig 1C ) . However, in patients with A(H1N1), levels of TRAP-stimulated PMA formation were lower in patients who died prior to hospital discharge (n 5 7/20, mortality rate 35%), compared with those who survived (55.8% Ϯ12.8% vs 72.7% Ϯ 5.0%, P P5 .16), although the difference did not reach significance. fi Because A(H1N1) infections are associated with cytokine release, we also measured plasma levels of IL-6 and TNF-a . Levels of IL-6 were undetectable in healthy control patients (eg, , 0.7 pg/mL) but elevated in patients with A(H1N1) and patients with pneumonia (130.4 Ϯ22.2 pg/mL vs 172.1 Ϯ6.0 pg/mL, P P5.43). Levels of IL-6 trended higher in patients with shock (140 Ϯ 51.0 vs 64 Ϯ 15.8, P 5 .07). Consistent with these data, IL-6 levels were weakly correlated with APACHE II scores in patients with pneumonia (r 2 5 0.24, P 5 .07) but did not correlate in patients with A(H1N1) (r 2 r r 5 0.0006, P 5 .92). IL-6 levels did not correlate with levels of PMA or PAC-1 binding in critically ill patients (81% in patients with A[H1N1] vs 87% in patients with pneumonia, P 5 not signifi-fi cant). The APACHE II scores were similar between groups ( Table 1 ) and, as expected, trended higher in patients with shock requiring vasopressors (22.6 Ϯ 9.5 vs 18.1 Ϯ 7.0, P P5.13). All patients with bacterial pneumonia had microbiologic testing performed, including blood and urine cultures, deep sputum culture, BAL, and infl uenza polymerase chain reaction. Overall, 60% (n 5 9 of 15) of patients with pneumonia had one or more pathogenic bacteria present in the sputum or BAL cultures. Staphylococcus aureus (56%) and Streptococcus (44%) were the organisms most commonly identifi ed, whereas Pseudomonas was rare (only one culture, 11%). In cultures where S aureus was present, pathogens recognized to be common causes of pneumonia (eg, Streptococcus ) were also frequently present. Only two patients with a positive sputum culture were diagnosed with S aureus pneumonia (frequency 13.3%). WBC and platelet counts on ICU admission were lower in patients with A(H1N1) compared with patients with bacterial pneumonia ( Table 1 ) . In-hospital, all-cause mortality was signifi-fi cantly higher in subjects with A(H1N1) than patients with bacterial pneumonia (35% vs 0%, P , .05).
Although platelets were activated in both critically ill patients with A(H1N1) and patients with bacterial pneumonia, the pattern of platelet activation was distinct. Baseline PMA formation was signifi-fi cantly higher in patients with A(H1N1) compared with healthy control subjects and trended higher compared with patients with bacterial pneumonia ( Fig 1A ) . Similarly, platelets from patients with A(H1N1) dem- a marker of platelet activation, in influenza-associated fl encephalopathy. 19 Patients with A(H1N1) also had increased platelet activation compared with patients with bacterial pneumonia of similar age, sex, and APACHE II scores ( Fig 1, Table 1 ), although differences in mechanical ventilation rates cannot be ignored. Furthermore, levels of PAC-1 binding were higher in patients with A(H1N1) with shock requiring vasopressor support, suggesting that the magnitude of platelet activation was greater in more severely ill patients. Although less than one-half of the patients had shock, despite the high admission APACHE II scores, these patients had higher levels of IL-6, consistent with cytokine synthesis inducing a systemic infl ammatory response fl and hypotension. 8, 10 Although the markers of in vivo platelet activation examined in these patients (eg, PMA and PAC-1) are not used for routine clinical management, their relevance as indices of systemic infl ammation and a hypercoagulable state has been demonstrated in similar disease states. Activation of platelets and leukocytes either group. Levels of TNF-a were undetectable in patients with A(H1N1) and patients with bacterial pneumonia (eg, , 5.5 pg/mL).
Discussion
A(H1N1), which reached pandemic proportions in 2009, commonly causes pulmonary infections leading to respiratory failure, systemic inflammation, and fl thrombosis. 3, 4, 18 Thrombocytopenia and leukopenia are common during viral respiratory infections, including influenza A, fl 4 and we observed similar presentations in our cohort ( Table 1 ) . To our knowledge, however, this is the fi rst report characterizing in vivo platelet activation in patients with ALI/ARDS due to primary A(H1N1). Patients with A(H1N1) had evidence of in vivo platelet activation with increased levels of PMA and PAC-1 binding compared with age-and sex-matched healthy control subjects. These data are consistent with published observations of platelet activation in ALI/ARDS from non-A(H1N1) infections 10 and descriptions of soluble CD40L release, ing and require additional investigation. Since ex vivo PMA formation in response to TRAP stimulation was not reduced when cells from infected patients were compared with healthy control subjects, these data suggest that A(H1N1) infection induces altered intracellular signaling pathways to a IIb b 3 activation distal to protease-activated receptor-1. 14, 16 The specific fi mechanism(s) remain to be explored.
The strengths of our study include the prospective study design, inclusion of matched control subjects and patients with bacterial pneumonia, and rigorous assessment of in vivo platelet activation by flow cytomfl etry. The primary limitation is the small sample size, as expected in a pilot study of this nature. In addition, we did not prospectively record specific details fi regarding the types of antibiotics prescribed or steroid administration, which may influence the infl fl amfl matory responses examined in this study. Nevertheless, our analysis identifi es key issues of pathophysiologic and clinical relevance for future investigations of larger scale.
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The sponsors had no role in the study design, patient recruitment, data collection and analysis, manuscript preparation, or submission. Other contributions: We thank Kim Mahoney, MS, Division of General Internal Medicine, for her assistance with figure prepafi ration. From the Program in Molecular Medicine, we thank Harry Men, BS, and Saritha Kalva, MS, for technical assistance . with formation of heterotypic PMAs in critical illness and infectious syndromes leads to amplified systemic fi infl ammatory responses and cytokine synthesis, confl tributing to lung injury, microvascular thrombosis, organ failure, and death. 10, 14 Similarly, PAC-1 is a monoclonal antibody that binds to the active conformation of integrin a IIb b 3 , a platelet surface receptor that binds fi brinogen mediating platelet adhesion and aggregation. The data in the current study support and extend prior reports of thrombotic events in A(H1N1) infections 5 by demonstrating that platelets-key mediators of thrombosis-are activated during A(H1N1). This in vivo platelet activation may also contribute to leukocyte and endothelial activation, further promoting thrombosis that contributes to organ failure and death.
In our study, patients with A(H1N1) also had a high incidence of in-hospital mortality, similar to other published observations. 3, 18 This high mortality may result from the marked systemic infl ammatory fl responses induced by A(H1N1).
In contrast, none of the patients with bacterial pneumonia died during their hospitalization, a somewhat unexpected fi nding given their requirements for mechanical ventilation and the average APACHE II score of 17.9. This low mortality rate may be attributable to their younger age (average age, 47 years) and relatively few comorbidities ( Table 1 ) , which are associated with a lower risk of mortality. 16, 20, 21 As matching was done blinded to all variables except age, sex, and APACHE II scores, the lower mortality of patients with bacterial pneumonia was unlikely to be due to inadvertent bias.
More than one-half of patients with pneumonia had a positive sputum of BAL culture result, thus helping to guide clinical management. Streptococcus was the most common cause of pneumonia, consistent with published studies. 16, 17, 22 S aureus pneumonia occurred in 13.3% of the patients. The prevalence of S aureus increases in patients with severe pneumonia requiring ICU-level care 16, 17, 23, 24 and in patients with healthcare associated pneumonia, although we did not capture this information from our cohort. 16, 17, 22 Plasma IL-6 levels, but not TNF-a, were elevated in patients with A(H1N1), consistent with published data 8 and indicating systemic inflammation consistent with our fl findings of activation of circulating platelets. IL-6 is fi a potent cytokine released during infl ammatory illfl nesses that has been reported to activate platelets 25, 26 and inhibit TNF-a release 27 and may also predict respi-7 ratory failure and mortality in critically ill subjects. 28, 29 These data support the key role of IL-6 in host defenses and exaggerated inflammatory responses. fl 30 Our findings of increased PAC-1 binding to unstimfi ulated platelets from patients with A(H1N1) but decreased PAC-1 binding upon TRAP stimulation of platelets from these subjects ex vivo ( Fig 1 ) are intrigu- 
